Figure 6. Comparison of the actuarial risk for developing BM.
A. between smoking and non-smoking; B. among patients with EGFR-TKIs first-line treatment, second-line treatment, and third-line or multi-line treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.